Carmat: positive publication in pulmonary hypertension

(CercleFinance.com) - Carmat announces the publication, in The Journal of Heart and Lung Transplantation, of a promising article on its Aeson artificial heart in patients suffering from heart failure with pulmonary hypertension, based on a study in Astana (Kazakhstan).


After implantation of the artificial heart, all three patients improved their functional capacity, as demonstrated by the six-minute walk test, and were discharged from hospital with Aeson support respectively 68, 48 and 48 days after implantation.

Over time, their pulmonary hypertension indicators improved, making them eligible for heart transplantation, which actually took place after 243, 155 and 109 days respectively.

'Up to 25% of patients with advanced heart failure suffer from pulmonary hypertension', stresses Carmat, for whom 'Aeson could become a standard treatment for these thousands of patients'.

Copyright (c) 2025 CercleFinance.com. All rights reserved.